$CRVS
Corvus Pharmaceuticals Inc
PRICE
$1.98 β²4.211%
Extented Hours
VOLUME
163,524
DAY RANGE
1.9 - 2
52 WEEK
0.607 - 4.19
Join Discuss about CRVS with like-minded investors
@Tom #T|T|T
@everone, wenn ihr also trades postet macht bistte Snaphot imt geplantem TP SL etc. ErklΓ€rungen warum wiso weshalb bitte erstmal lassen. Wir mΓΆchten uns erst einen Eindruck von der QualitΓ€t der trades verschaffen, insbesondere im HInblick auf die CRVs
84 Replies 7 π 10 π₯
@Matthias_Knopf #T|T|T
Ok ich lass es. keine Trades mehr. Intraday komm ich einfach auf keine CRVs die man da benΓΆtigen wΓΌrde :)
143 Replies 8 π 7 π₯
@Baljit123 #StockTraders.NET
MIC CHRIS LEE WATCHLIST. Not many I really like its been slow and no follow through on the runners 1. CRVS multi day runner had a nice FGD we will see if we can get some continuation 2. IRNT they seem to be trying to push this up PR;s keep coming out with PT raises 3. OPAD still hovering the 10 line just watching 4. ATER still holding the multiday uptrend and reclaimed the 10 day and above the 20 day on the daily might make another bun at 20 line and the daily range is getting tighter 5. DNA is SPAC merger it has been on a multiday uptrend if it gets over the 14.25 ATH could see a nice move but this is not really the market for strong continuation so we will have to watch and see
141 Replies 12 π 7 π₯
@TraderXx #StockTraders.NET
$CRVS might have a trick up it sleeve towards EOD, expecting some kinda blast and a sit back
149 Replies 10 π 6 π₯
@TraderXx #StockTraders.NET
I see $CRVS being forgotten kinda, need to keep an eye on this one
106 Replies 15 π 10 π₯
@maletone #StockTraders.NET
sold most my $CRVS but wished i went short after I sold lol
148 Replies 10 π 14 π₯
Key Metrics
Market Cap
93.17 M
Beta
2.32
Avg. Volume
211.66 K
Shares Outstanding
49.04 M
Yield
0%
Public Float
0
Next Earnings Date
2024-03-28
Next Dividend Date
Company Information
corvus pharmaceuticals is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class agents that target the immune system to treat patients with cancer. with accomplished and talented scientists, and top-tier investors, we are well positioned in an exciting new era of immuno-oncology.
CEO: Richard Miller
Website: http://www.corvuspharma.com/
HQ: 863 Mitten Rd Ste 102 Burlingame, 94010-1311 California
Related News